Biogen Inc. Files 8-K: Fiscal Year Change and Shareholder Matters
Ticker: BIIB · Form: 8-K · Filed: 2024-06-25T00:00:00.000Z
Sentiment: neutral
Topics: corporate-governance, financial-reporting, fiscal-year-change
Related Tickers: BIIB
TL;DR
Biogen's changing fiscal year end to Dec 31st, plus shareholder votes and financials filed.
AI Summary
Biogen Inc. filed an 8-K on June 25, 2024, reporting events that occurred on June 20, 2024. The filing indicates a change in the company's fiscal year end to December 31st, and also includes information regarding the submission of matters to a vote of security holders and financial statements. The company is incorporated in Delaware and headquartered at 225 Binney Street, Cambridge, MA.
Why It Matters
This filing signals a change in Biogen's financial reporting calendar and includes updates on corporate governance and financial disclosures, which are important for investors tracking the company's performance and regulatory compliance.
Risk Assessment
Risk Level: low — The filing primarily concerns administrative and reporting changes, not significant operational or financial distress.
Key Numbers
- 0-19311 — SEC File Number (Biogen's SEC filing identifier)
- 33-0112644 — IRS Employer Identification No. (Biogen's tax identification number)
Key Players & Entities
- Biogen Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 225 Binney Street, Cambridge, MA (location) — Business address
- June 20, 2024 (date) — Earliest event reported
- June 25, 2024 (date) — Filing date
- December 31 (date) — New fiscal year end
FAQ
What is the new fiscal year end for Biogen Inc.?
Biogen Inc.'s fiscal year end has been changed to December 31.
On what date were the events reported in this 8-K first reported?
The earliest event reported in this 8-K occurred on June 20, 2024.
What is Biogen Inc.'s state of incorporation?
Biogen Inc. is incorporated in Delaware.
What is the business address of Biogen Inc.?
The business address of Biogen Inc. is 225 Binney Street, Cambridge, MA.
What are the main items covered in this 8-K filing?
This 8-K filing covers amendments to articles of incorporation or bylaws, submission of matters to a vote of security holders, and financial statements and exhibits.
Filing Stats: 925 words · 4 min read · ~3 pages · Grade level 10.9 · Accepted 2024-06-25 17:01:02
Key Financial Figures
- $0.0005 — nge on which registered Common Stock, $0.0005 par value BIIB The Nasdaq Global Se
Filing Documents
- d840763d8k.htm (8-K) — 64KB
- d840763dex31.htm (EX-3.1) — 6KB
- g840763g0622075048132.jpg (GRAPHIC) — 2KB
- 0001193125-24-167938.txt ( ) — 201KB
- biib-20240620.xsd (EX-101.SCH) — 3KB
- biib-20240620_lab.xml (EX-101.LAB) — 18KB
- biib-20240620_pre.xml (EX-101.PRE) — 11KB
- d840763d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The exhibits listed below are furnished as part of this Current Report on Form 8-K. Exhibit No. Description 3.1 Certificate of Amendment of Biogen Inc.'s Amended and Restated Certificate of Incorporation, as amended. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Biogen Inc. By: /s/ Wendell Taylor Wendell Taylor Secretary Date: June 25, 2024 3